Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $6.7 million.

  • Denali Therapeutics' Accounts Payables fell 2969.56% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 2969.56%. This contributed to the annual value of $11.1 million for FY2024, which is 1744.17% up from last year.
  • As of Q3 2025, Denali Therapeutics' Accounts Payables stood at $6.7 million, which was down 2969.56% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Accounts Payables ranged from a high of $13.9 million in Q2 2024 and a low of $1.6 million during Q1 2021
  • Its 5-year average for Accounts Payables is $7.7 million, with a median of $8.5 million in 2025.
  • As far as peak fluctuations go, Denali Therapeutics' Accounts Payables skyrocketed by 34621.85% in 2021, and later plummeted by 4161.96% in 2022.
  • Denali Therapeutics' Accounts Payables (Quarter) stood at $4.8 million in 2021, then crashed by 41.62% to $2.8 million in 2022, then surged by 239.89% to $9.5 million in 2023, then increased by 17.44% to $11.1 million in 2024, then plummeted by 39.44% to $6.7 million in 2025.
  • Its Accounts Payables was $6.7 million in Q3 2025, compared to $10.8 million in Q2 2025 and $8.5 million in Q1 2025.